Sugar High: How a Glucose Monitor Told Me Startling Things About My Diet
Little did I realize a few grapes could send my blood sugar soaring until I tried the first glucose monitor without a ...
Wells Fargo Sticks to Their Buy Rating for Dexcom (DXCM)
Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) yesterday and set a price target of ...
Endocrinology Advisor3d
Long-Term CGM System Eversense 365 Gets FDA Clearance
The FDA has designated the Eversense 365 an integrated CGM, allowing for integration with compatible medical devices. The ...
DexCom: Investors Discounting Long CGM Growth Runway
DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...
Econsultancy3d
Dexcom expands Continuous Glucose Monitoring coverage to 14 million globally with help of integrated #SeeDiabetes campaign
The company, which manufactures CGM devices, partnered with Allison PR for a campaign that aimed to spread awareness of life ...
Medscape4d
CGM Cuts Hospitalization in T2D, Even in Non-Insulin Treated
Real-world data showed reductions in healthcare resource utilization and improved glycemic control over 1 year with ...
Dexcom Brings Mentorship to Centerfield, Welcomes New, Star Athletes to Its Ground-breaking NIL Program Dexcom U
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, ...
drugdeliverybusiness5d
Senseonics wins FDA nod for 365-day implantable CGM
Senseonics (NYSE:SENS) announced today that it received FDA clearance for its next-generation Eversense 365 CGM system.
BioWorld5d
FDA clears Senseonic’s Eversense one-year implantable CGM
The U.S. FDA cleared Senseonic Holdings Inc.’s Eversense 365, the first continuous glucose monitor to last a full year with a single sensor rather than the 10 days to two weeks typical for wearable ...
Senseonics Holdings, Inc.: Eversense 365 Receives FDA Clearance: The World's First One Year CGM
Eversense 365 cleared in the U.S. as an integrated continuous glucose monitoring (iCGM) system for people with diabetes With a single sensor, the Eversense 365 system provides one year of use, versus ...
Uh-Oh! Alphabet Is Selling Its Stake in 2 Historically High-Flying Artificial Intelligence (AI) Stocks
These once-sizable artificial intelligence (AI) holdings for Google parent Alphabet have been paired down big-time over the ...
Wells Fargo Remains a Buy on Dexcom (DXCM)
Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) on September 13 and set a price target of ...